Developing a new platform to find antibiotics from natural sources
A Next-Generation Scalable Platform to Discover Antimicrobials of Ribosomal Origin
This study is looking for new antibiotics made from natural sources to help fight tough bacterial infections that don't respond to current treatments, so patients can have better options for getting well.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Urbana-Champaign NIH-funded |
| Lab location | 1 site (Champaign, United States) |
| Project ID | NIH-11126685 on NIH RePORTER |
What this research studies
This research focuses on discovering new antibiotics derived from natural products, specifically ribosomally synthesized and post-translationally modified peptides (RiPPs). The team utilizes advanced genomic technologies and synthetic biology to enhance the discovery process, aiming to overcome the challenges posed by antibiotic resistance, particularly against Gram-negative bacteria. By creating a fully automated and scalable pipeline, the project seeks to identify and produce effective new antimicrobial agents that can be used in clinical settings. Patients may benefit from the development of new antibiotics that can effectively treat resistant bacterial infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from infections caused by antibiotic-resistant bacteria.
Not a fit: Patients with infections that are not caused by bacterial pathogens or those who do not have antibiotic-resistant infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antibiotics that effectively combat antibiotic-resistant infections.
How similar studies have performed: Previous research has shown promise in utilizing natural products for antibiotic development, indicating that this approach has the potential for success.
Where this research is happening
Champaign, United States
- University of Illinois at Urbana-Champaign — Champaign, United States (Active)
Researchers
- Principal investigator: Zhao, Huimin — University of Illinois at Urbana-Champaign
- Study coordinator: Zhao, Huimin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.